MEDNAX Stock Price, News & Analysis (NYSE:MD)

$56.43 -0.18 (-0.32 %)
(As of 02/20/2018 04:00 PM ET)
Previous Close$56.61
Today's Range$55.80 - $56.67
52-Week Range$40.56 - $72.13
Volume1.42 million shs
Average Volume971,859 shs
Market Capitalization$5.28 billion
P/E Ratio16.36
Dividend YieldN/A
Beta0.31

About MEDNAX (NYSE:MD)

MEDNAX logoMEDNAX, Inc. is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company's national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. As of December 31, 2016, the Company had over 1,390 affiliated physicians providing anesthesia care to patients in connection with surgical and other procedures, as well as pain management. As of December 31, 2016, the Company had 270 affiliated physicians providing maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.

Receive MD News and Ratings via Email

Sign-up to receive the latest news and ratings for MD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Healthcare Facilities & Services
Sub-IndustryHealth Care Services
SectorHealthcare
SymbolNYSE:MD
CUSIP58502B10
Phone+1-954-3840175

Debt

Debt-to-Equity Ratio0.60%
Current Ratio1.18%
Quick Ratio1.18%

Price-To-Earnings

Trailing P/E Ratio16.3565217391304
Forward P/E Ratio13.97
P/E Growth1.4

Sales & Book Value

Annual Sales$3.46 billion
Price / Sales1.53
Cash Flow$4.27 per share
Price / Cash13.23
Book Value$32.74 per share
Price / Book1.72

Profitability

Trailing EPS$3.45
Net Income$320.37 million
Net Margins9.26%
Return on Equity10.10%
Return on Assets5.23%

Miscellaneous

Employees7,675
Outstanding Shares93,800,000

MEDNAX (NYSE:MD) Frequently Asked Questions

What is MEDNAX's stock symbol?

MEDNAX trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."

How were MEDNAX's earnings last quarter?

MEDNAX Inc (NYSE:MD) released its quarterly earnings data on Thursday, February, 8th. The company reported $0.87 earnings per share for the quarter, topping analysts' consensus estimates of $0.83 by $0.04. The firm earned $910.82 million during the quarter, compared to analyst estimates of $884.55 million. MEDNAX had a return on equity of 10.10% and a net margin of 9.26%. The business's quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.00 earnings per share. View MEDNAX's Earnings History.

When will MEDNAX make its next earnings announcement?

MEDNAX is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for MEDNAX.

What guidance has MEDNAX issued on next quarter's earnings?

MEDNAX updated its first quarter earnings guidance on Thursday, February, 8th. The company provided earnings per share (EPS) guidance of $0.84-0.89 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.79.

Where is MEDNAX's stock going? Where will MEDNAX's stock price be in 2018?

12 brokerages have issued 12-month price targets for MEDNAX's stock. Their forecasts range from $47.00 to $62.00. On average, they anticipate MEDNAX's stock price to reach $54.45 in the next year. View Analyst Ratings for MEDNAX.

Who are some of MEDNAX's key competitors?

Who are MEDNAX's key executives?

MEDNAX's management team includes the folowing people:

  • Cesar L. Alvarez, Chairman of the Board (Age 69)
  • Joseph M. Calabro, President, Chief Operating Officer (Age 56)
  • Roger J. Medel M.D., Chief Executive Officer, Director (Age 70)
  • Vivian Lopez-Blanco, Chief Financial Officer, Treasurer (Age 59)
  • David A. Clark, President - MEDNAX National Medical Group Division (Age 50)
  • John C. Pepia, Senior Vice President, Chief Accounting Officer (Age 54)
  • Dominic J. Andreano, Senior Vice President, General Counsel, Secretary (Age 48)
  • Manuel Kadre, Lead Independent Director (Age 51)
  • Karey D. Barker, Independent Director (Age 49)
  • Waldemar A. Carlo M.D., Independent Director (Age 64)

Who owns MEDNAX stock?

MEDNAX's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.27%), Earnest Partners LLC (2.36%), Wedge Capital Management L L P NC (2.24%), ArrowMark Colorado Holdings LLC (1.62%), HealthCor Management L.P. (1.35%) and Bank of New York Mellon Corp (1.32%). Company insiders that own MEDNAX stock include Cesar L Alvarez, Dominic J Andreano, Enrique Sosa, John C Pepia, Joseph M Calabro, Karl B Wagner, Manuel Kadre, Md Carlo A Waldemar, Md Pascal J Goldschmidt, Michael D Stanley, Paul G Gabos, Robert Irwin Valliant and Vivian Lopez-Blanco. View Institutional Ownership Trends for MEDNAX.

Who sold MEDNAX stock? Who is selling MEDNAX stock?

MEDNAX's stock was sold by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, BlackRock Inc., Millennium Management LLC, Deutsche Bank AG, Toronto Dominion Bank, Sterling Capital Management LLC, Swiss National Bank and Cooke & Bieler LP. Company insiders that have sold MEDNAX company stock in the last year include Cesar L Alvarez, Enrique Sosa, John C Pepia, Joseph M Calabro, Md Pascal J Goldschmidt, Robert Irwin Valliant and Vivian Lopez-Blanco. View Insider Buying and Selling for MEDNAX.

Who bought MEDNAX stock? Who is buying MEDNAX stock?

MEDNAX's stock was purchased by a variety of institutional investors in the last quarter, including HealthCor Management L.P., Pzena Investment Management LLC, Earnest Partners LLC, Wells Fargo & Company MN, First Trust Advisors LP, BTIM Corp., 13D Management LLC and Bank of Montreal Can. Company insiders that have bought MEDNAX stock in the last two years include Manuel Kadre and Md Pascal J Goldschmidt. View Insider Buying and Selling for MEDNAX.

How do I buy MEDNAX stock?

Shares of MEDNAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MEDNAX's stock price today?

One share of MEDNAX stock can currently be purchased for approximately $56.43.

How big of a company is MEDNAX?

MEDNAX has a market capitalization of $5.28 billion and generates $3.46 billion in revenue each year. The company earns $320.37 million in net income (profit) each year or $3.45 on an earnings per share basis. MEDNAX employs 7,675 workers across the globe.

How can I contact MEDNAX?

MEDNAX's mailing address is 1301 Concord Ter, SUNRISE, FL 33323-2843, United States. The company can be reached via phone at +1-954-3840175 or via email at [email protected]


MarketBeat Community Rating for MEDNAX (MD)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  290 (Vote Outperform)
Underperform Votes:  327 (Vote Underperform)
Total Votes:  617
MarketBeat's community ratings are surveys of what our community members think about MEDNAX and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MEDNAX (NYSE:MD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.172.172.092.00
Ratings Breakdown: 1 Sell Rating(s)
8 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $54.45$53.82$54.50$61.00
Price Target Upside: 0.95% upside2.45% upside25.66% upside29.84% upside

MEDNAX (NYSE:MD) Consensus Price Target History

Price Target History for MEDNAX (NYSE:MD)

MEDNAX (NYSE:MD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/12/2018BMO Capital MarketsBoost Price TargetMarket Perform -> Market Perform$46.00 -> $58.00LowView Rating Details
2/12/2018JPMorgan Chase & Co.Boost Price TargetNeutral -> Neutral$46.00 -> $55.00LowView Rating Details
2/9/2018MizuhoReiterated RatingNeutral -> Neutral$49.00 -> $53.00LowView Rating Details
2/9/2018Robert W. BairdBoost Price TargetNeutral -> Neutral$48.00 -> $54.00MediumView Rating Details
2/8/2018StephensSet Price TargetBuy$62.00MediumView Rating Details
2/6/2018Jefferies GroupSet Price TargetHold$50.00MediumView Rating Details
1/24/2018Stifel NicolausReiterated RatingHold$56.00LowView Rating Details
12/21/2017SunTrust BanksSet Price TargetHold$55.00MediumView Rating Details
12/13/2017Piper Jaffray CompaniesInitiated CoverageOverweight -> Overweight$58.00LowView Rating Details
11/3/2017CitigroupLower Price TargetNeutral$52.00 -> $47.00N/AView Rating Details
11/1/2017KeyCorpSet Price TargetBuy$51.00N/AView Rating Details
5/4/2017Bank of AmericaDowngradeBuy -> UnderperformLowView Rating Details
12/9/2016Goldman Sachs GroupInitiated CoverageNeutral$66.00N/AView Rating Details
10/27/2016Raymond James FinancialDowngradeOutperform -> Market PerformN/AView Rating Details
3/7/2016Susquehanna BancsharesDowngradePositive -> Neutral$94.00 -> $70.00N/AView Rating Details
(Data available from 2/20/2016 forward)

Earnings

MEDNAX (NYSE:MD) Earnings History and Estimates Chart

Earnings by Quarter for MEDNAX (NYSE:MD)

MEDNAX (NYSE MD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018$0.82N/AView Earnings Details
2/8/2018Q4 2017$0.83$0.87$884.55 million$910.82 millionViewN/AView Earnings Details
11/1/2017Q3 2017$0.87$0.87$864.78 million$868.95 millionViewN/AView Earnings Details
7/28/2017Q2 2017$0.81$0.85$849.49 million$843.00 millionViewN/AView Earnings Details
5/4/2017Q1 2017$0.74$0.75$837.01 million$835.60 millionViewN/AView Earnings Details
4/20/2017Q1 2017$0.81$0.70$839.25 million$836.00 millionViewN/AView Earnings Details
2/7/2017Q416$1.06$1.00$842.15 million$831.00 millionViewListenView Earnings Details
10/27/2016Q316$1.05$1.09$821.18 million$828.00 millionViewListenView Earnings Details
7/28/2016Q216$1.07$1.03$775.68 million$772.00 millionViewListenView Earnings Details
4/28/2016Q116$0.86$0.87$741.49 million$752.60 millionViewListenView Earnings Details
2/4/2016Q415$1.10$1.13$748.02 million$742.00 millionViewListenView Earnings Details
10/29/2015Q315$0.97$1.10$730.63 million$722.30 millionViewListenView Earnings Details
7/30/2015Q215$0.88$0.97$677.02 million$676.60 millionViewListenView Earnings Details
4/30/2015Q115$0.71$0.72$641.24 million$639.40 millionViewListenView Earnings Details
1/29/2015Q414$0.87$0.89$637.90 million$651.00 millionViewListenView Earnings Details
10/30/2014Q314$0.85$0.86$619.61 million$627.00 millionViewListenView Earnings Details
7/31/2014Q214$0.78$0.79$603.00 million$595.54 millionViewListenView Earnings Details
5/1/2014Q114$0.63$0.63$574.80 million$566.00 millionViewListenView Earnings Details
1/30/2014Q4$0.75$0.20$555.30 million$567.00 millionViewListenView Earnings Details
10/31/2013Q313$1.48$1.52$556.63 million$555.00 millionViewListenView Earnings Details
7/30/2013Q2 2013$1.36$1.37$533.39 million$529.18 millionViewListenView Earnings Details
5/2/2013Q1 2013$1.09$1.10$504.24 million$502.70 millionViewListenView Earnings Details
1/31/2013Q4 2012$1.30$1.32$473.70 million$471.30 millionViewListenView Earnings Details
11/1/2012Q312$1.28$1.32$470.60 million$473.10 millionViewN/AView Earnings Details
7/31/2012$1.19$1.22ViewN/AView Earnings Details
5/3/2012$1.00$0.98ViewN/AView Earnings Details
2/2/2012$1.19$1.19ViewN/AView Earnings Details
11/1/2011$1.18$1.19ViewN/AView Earnings Details
8/2/2011$1.15$1.15ViewN/AView Earnings Details
5/3/2011$0.91$0.94ViewN/AView Earnings Details
2/3/2011$1.12$1.12ViewN/AView Earnings Details
11/2/2010Q3 2010$0.53$0.53ViewN/AView Earnings Details
8/3/2010Q2 2010$0.51$0.52ViewN/AView Earnings Details
5/3/2010Q1 2010$0.41$0.41ViewN/AView Earnings Details
2/5/2010Q4 2009$0.49$0.50ViewN/AView Earnings Details
11/2/2009Q3 2009$0.48$0.52ViewN/AView Earnings Details
8/4/2009Q2 2009$0.43$0.47ViewN/AView Earnings Details
5/7/2009Q1 2009$0.33$0.37ViewN/AView Earnings Details
2/5/2009Q4 2008$0.39$0.41ViewN/AView Earnings Details
11/5/2008Q3 2008$0.41$0.41ViewN/AView Earnings Details
8/5/2008Q2 2008$0.39$0.40ViewN/AView Earnings Details
5/8/2008Q1 2008$0.34$0.33ViewN/AView Earnings Details
2/6/2008Q4 2007$0.40$0.40ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

MEDNAX (NYSE:MD) Earnings Estimates

2018 EPS Consensus Estimate: $3.91
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.80$0.80$0.80
Q2 20181$1.02$1.02$1.02
Q3 20181$1.06$1.06$1.06
Q4 20181$1.03$1.03$1.03
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for MEDNAX (NYSE:MD)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

MEDNAX (NYSE MD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.40%
Institutional Ownership Percentage: 95.12%
Insider Trades by Quarter for MEDNAX (NYSE:MD)
Insider Trades by Quarter for MEDNAX (NYSE:MD)

MEDNAX (NYSE MD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/12/2017John C PepiaInsiderSell3,000$51.58$154,740.0035,569View SEC Filing  
11/3/2017Cesar L AlvarezDirectorSell10,668$42.59$454,350.1244,215View SEC Filing  
9/12/2017John C PepiaInsiderSell3,000$42.85$128,550.0035,569View SEC Filing  
6/14/2017Md Pascal J GoldschmidtDirectorSell1,969$57.57$113,355.3318,072View SEC Filing  
6/1/2017Joseph M CalabroInsiderSell23,327$55.00$1,282,985.00296,379View SEC Filing  
5/5/2017Manuel KadreDirectorBuy21,704$55.79$1,210,866.16111,255View SEC Filing  
5/5/2017Vivian Lopez-BlancoCFOSell7,778$55.82$434,167.9651,319View SEC Filing  
3/16/2017Robert Irwin ValliantDirectorSell5,200$1.10$5,720.00
2/23/2017Enrique SosaDirectorSell10,668$69.65$743,026.2021,923View SEC Filing  
2/17/2017Vivian Lopez-BlancoCFOSell15,164$70.01$1,061,631.6459,097View SEC Filing  
2/16/2017Dominic J AndreanoSVPSell6,000$69.59$417,540.0030,746View SEC Filing  
2/16/2017John C PepiaInsiderSell2,500$69.58$173,950.0031,025View SEC Filing  
2/16/2017Paul G GabosDirectorSell21,336$69.63$1,485,625.6821,923View SEC Filing  
2/10/2017Md Pascal J GoldschmidtDirectorSell25,294$67.82$1,715,439.0814,173View SEC Filing  
2/9/2017Md Carlo A WaldemarDirectorSell5,334$67.90$362,178.6016,589View SEC Filing  
1/17/2017Vivian Lopez-BlancoCFOSell10,000$70.95$709,500.0074,261View SEC Filing  
12/7/2016Md Pascal J GoldschmidtDirectorBuy2,100$66.52$139,692.0013,355View SEC Filing  
9/14/2016Md Pascal J GoldschmidtDirectorSell1,500$65.01$97,515.0012,755View SEC Filing  
6/13/2016Dominic J AndreanoSVPSell3,922$68.80$269,833.6024,746View SEC Filing  
6/8/2016Md Carlo A WaldemarDirectorSell5,334$70.50$376,047.0016,589View SEC Filing  
6/7/2016Karl B WagnerInsiderSell27,482$68.45$1,881,142.90105,932View SEC Filing  
6/1/2016Joseph M CalabroCOOSell28,347$67.78$1,921,359.66253,882View SEC Filing  
6/1/2016Michael D StanleyInsiderSell14,778$67.78$1,001,652.8449,266View SEC Filing  
5/16/2016Dominic J AndreanoSVPSell3,000$68.53$205,590.0021,313View SEC Filing  
5/2/2016Vivian Lopez-BlancoCFOSell9,350$71.22$665,907.0064,083View SEC Filing  
3/11/2016Md Pascal J GoldschmidtDirectorSell3,100$65.00$201,500.0012,479View SEC Filing  
2/29/2016Paul G GabosDirectorSell10,668$67.15$716,356.2020,047View SEC Filing  
12/11/2015Md Pascal J. GoldschmidtDirectorSell5,250$70.99$372,697.509,379View SEC Filing  
9/8/2015Cesar L. AlvarezDirectorSell10,668$81.00$864,108.0029,379View SEC Filing  
8/27/2015Roger Md MedelCEOSell100,000$80.27$8,027,000.001,199,708View SEC Filing  
6/8/2015Karl B WagnerInsiderSell37,820$70.28$2,657,989.60View SEC Filing  
6/3/2015Joseph M CalabroCOOSell108,071$70.51$7,620,086.21View SEC Filing  
3/9/2015Md Pascal J GoldschmidtDirectorSell8,500$71.25$605,625.00View SEC Filing  
2/26/2015Roger Md MedelCEOSell100,000$71.61$7,161,000.00View SEC Filing  
2/20/2015Md Carlo A WaldemarDirectorSell10,668$71.50$762,762.00View SEC Filing  
2/6/2015Dominic J AndreanoSVPSell3,200$70.75$226,400.00View SEC Filing  
2/6/2015Vivian Lopez-BlancoCFOSell8,250$69.95$577,087.50View SEC Filing  
2/2/2015Paul G GabosDirectorSell17,584$68.07$1,196,942.88View SEC Filing  
1/30/2015William C HawkCOOSell3,598$68.50$246,463.00View SEC Filing  
11/14/2014Roger Md MedelCEOSell51,290$62.59$3,210,241.10View SEC Filing  
11/13/2014Roger Md MedelCEOSell63,440$62.55$3,968,172.00View SEC Filing  
11/7/2014Roger Md MedelCEOSell128,833$62.60$8,064,945.80View SEC Filing  
11/5/2014Roger Md MedelCEOSell169,845$62.60$10,632,297.00View SEC Filing  
11/4/2014Roger Md MedelCEOSell15,052$62.52$941,051.04View SEC Filing  
11/3/2014Roger Md MedelCEOSell10,881$62.52$680,280.12View SEC Filing  
10/31/2014Roger Md MedelCEOSell61,592$62.58$3,854,427.36View SEC Filing  
10/30/2014Karl B WagnerInsiderSell40,000$62.50$2,500,000.00View SEC Filing  
10/30/2014Vivian Lopez-BlancoCFOSell8,800$60.00$528,000.00View SEC Filing  
7/30/2014Karl B WagnerInsiderSell80,000$60.00$4,800,000.00View SEC Filing  
6/10/2014Dominic J AndreanoSVPSell2,252$58.48$131,696.96View SEC Filing  
6/6/2014Karl B WagnerInsiderSell44,596$58.53$2,610,203.88View SEC Filing  
6/5/2014William C HawkCOOSell6,911$57.66$398,488.26View SEC Filing  
6/2/2014David A ClarkCOOSell16,230$57.00$925,110.00View SEC Filing  
6/2/2014Michael D StanleyInsiderSell18,006$57.00$1,026,342.00View SEC Filing  
5/9/2014Karl WagnerInsiderSell79,524$57.09$4,540,025.16150,498View SEC Filing  
5/9/2014Md Pascal GoldschmidtDirectorSell30,000$57.11$1,713,300.005,350View SEC Filing  
5/8/2014Joseph CalabroCOOSell137,500$57.06$7,845,750.00226,542View SEC Filing  
2/20/2014Dominic AndreanoSVPSell3,000$61.00$183,000.0016,135View SEC Filing  
2/10/2014Joseph CalabroCOOSell150,000$55.55$8,332,500.00226,542View SEC Filing  
2/10/2014Md Carlo WaldemarDirectorSell10,668$55.40$591,007.205,350View SEC Filing  
11/7/2013Enrique SosaDirectorSell5,334$107.00$570,738.002,675View SEC Filing  
11/7/2013Karl WagnerInsiderSell1,800$107.60$193,680.0075,249View SEC Filing  
9/11/2013William C HawkCOOSell3,162$100.62$318,160.44View SEC Filing  
9/10/2013Dominic J AndreanoSVPSell3,718$99.63$370,424.34View SEC Filing  
8/7/2013Karl WagnerInsiderSell25,000$98.01$2,450,250.0075,249View SEC Filing  
8/2/2013Joseph M CalabroCOOSell36,154$98.57$3,563,699.78View SEC Filing  
6/3/2013David A ClarkCOOSell8,645$91.01$786,781.45View SEC Filing  
6/3/2013Michael D StanleyInsiderSell8,906$91.01$810,535.06View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

MEDNAX (NYSE MD) News Headlines

Source:
DateHeadline
Paul Singers Top 5 New BuysPaul Singer's Top 5 New Buys
finance.yahoo.com - February 20 at 4:24 PM
BMO Capital Markets Boosts MEDNAX (MD) Price Target to $58.00BMO Capital Markets Boosts MEDNAX (MD) Price Target to $58.00
www.americanbankingnews.com - February 12 at 11:50 AM
Analyzing MEDNAX (MD) and LifePoint Health (LPNT)Analyzing MEDNAX (MD) and LifePoint Health (LPNT)
www.americanbankingnews.com - February 12 at 11:36 AM
JPMorgan Chase & Co. Increases MEDNAX (MD) Price Target to $55.00JPMorgan Chase & Co. Increases MEDNAX (MD) Price Target to $55.00
www.americanbankingnews.com - February 12 at 10:08 AM
MEDNAX (MD) PT Set at $62.00 by StephensMEDNAX (MD) PT Set at $62.00 by Stephens
www.americanbankingnews.com - February 10 at 3:34 PM
MEDNAX (MD) Earns Hold Rating from MizuhoMEDNAX (MD) Earns Hold Rating from Mizuho
www.americanbankingnews.com - February 10 at 6:28 AM
MEDNAX (MD) Price Target Raised to $54.00 at Robert W. BairdMEDNAX (MD) Price Target Raised to $54.00 at Robert W. Baird
www.americanbankingnews.com - February 10 at 12:18 AM
MEDNAX Sees Unusually High Options Volume (MD)MEDNAX Sees Unusually High Options Volume (MD)
www.americanbankingnews.com - February 9 at 1:12 AM
Reviewing MEDNAX (MD) & Kindred Healthcare (KND)Reviewing MEDNAX (MD) & Kindred Healthcare (KND)
www.americanbankingnews.com - February 8 at 7:02 PM
FY2018 EPS Estimates for MEDNAX Inc Raised by Jefferies Group (MD)FY2018 EPS Estimates for MEDNAX Inc Raised by Jefferies Group (MD)
www.americanbankingnews.com - February 8 at 1:22 PM
MEDNAX (MD) Releases  Earnings Results, Beats Expectations By $0.04 EPSMEDNAX (MD) Releases Earnings Results, Beats Expectations By $0.04 EPS
www.americanbankingnews.com - February 8 at 10:58 AM
MEDNAX (MD) Releases Q1 Earnings GuidanceMEDNAX (MD) Releases Q1 Earnings Guidance
www.americanbankingnews.com - February 8 at 9:56 AM
MEDNAX, Inc. to Host Earnings CallMEDNAX, Inc. to Host Earnings Call
finance.yahoo.com - February 8 at 9:13 AM
Mednax beats Street 4Q forecastsMednax beats Street 4Q forecasts
finance.yahoo.com - February 8 at 9:13 AM
MEDNAX Reports Fourth Quarter GAAP EPS of $1.46MEDNAX Reports Fourth Quarter GAAP EPS of $1.46
finance.yahoo.com - February 8 at 9:13 AM
Analysts Offer Predictions for MEDNAX Incs Q1 2018 Earnings (MD)Analysts Offer Predictions for MEDNAX Inc's Q1 2018 Earnings (MD)
www.americanbankingnews.com - February 7 at 8:08 AM
Comparing MEDNAX (MD) and LifePoint Health (LPNT)Comparing MEDNAX (MD) and LifePoint Health (LPNT)
www.americanbankingnews.com - February 7 at 3:08 AM
MEDNAX Inc (MD) Expected to Post Quarterly Sales of $887.77 MillionMEDNAX Inc (MD) Expected to Post Quarterly Sales of $887.77 Million
www.americanbankingnews.com - February 7 at 2:32 AM
MEDNAX Inc (MD) Given Average Recommendation of "Hold" by BrokeragesMEDNAX Inc (MD) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 2 at 1:46 PM
MEDNAX (MD) Set to Announce Quarterly Earnings on MondayMEDNAX (MD) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - January 29 at 3:38 AM
Mizuho Analysts Give MEDNAX (MD) a $49.00 Price TargetMizuho Analysts Give MEDNAX (MD) a $49.00 Price Target
www.americanbankingnews.com - January 24 at 11:52 PM
Stifel Nicolaus Reaffirms Hold Rating for MEDNAX (MD)Stifel Nicolaus Reaffirms Hold Rating for MEDNAX (MD)
www.americanbankingnews.com - January 24 at 9:50 AM
MEDNAX’s American Anesthesiology to Exhibit at ASA’s PRACTICE MANAGEMENT 2018 Jan. 26-27MEDNAX’s American Anesthesiology to Exhibit at ASA’s PRACTICE MANAGEMENT 2018 Jan. 26-27
finance.yahoo.com - January 23 at 8:42 AM
MEDNAX (MD) Upgraded to "Buy" at Zacks Investment ResearchMEDNAX (MD) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 23 at 6:12 AM
MEDNAX 2017 Fourth Quarter Conference Call/Webcast Scheduled for Thursday, February 8, 2018MEDNAX 2017 Fourth Quarter Conference Call/Webcast Scheduled for Thursday, February 8, 2018
finance.yahoo.com - January 22 at 5:28 PM
Zacks: Analysts Expect MEDNAX Inc (MD) Will Announce Quarterly Sales of $886.36 MillionZacks: Analysts Expect MEDNAX Inc (MD) Will Announce Quarterly Sales of $886.36 Million
www.americanbankingnews.com - January 21 at 2:02 AM
$0.84 EPS Expected for MEDNAX Inc (MD) This Quarter$0.84 EPS Expected for MEDNAX Inc (MD) This Quarter
www.americanbankingnews.com - January 19 at 9:26 PM
The Providence Service (PRSC) and MEDNAX (MD) Financial ComparisonThe Providence Service (PRSC) and MEDNAX (MD) Financial Comparison
www.americanbankingnews.com - January 18 at 5:08 AM
Active-Investors: Wired News - MEDNAX Acquires California-Based Neonatology PracticeActive-Investors: Wired News - MEDNAX Acquires California-Based Neonatology Practice
www.finanznachrichten.de - January 12 at 9:38 AM
Wired News – MEDNAX Acquires California-Based Neonatology PracticeWired News – MEDNAX Acquires California-Based Neonatology Practice
finance.yahoo.com - January 12 at 9:38 AM
MEDNAX (MD) Reports Acquisition of Neonatology Practice in CaliforniaMEDNAX (MD) Reports Acquisition of Neonatology Practice in California
www.streetinsider.com - January 10 at 5:15 PM
MEDNAX Announces Acquisition of Neonatology Practice in CaliforniaMEDNAX Announces Acquisition of Neonatology Practice in California
finance.yahoo.com - January 10 at 9:37 AM
MEDNAX Inc (MD) Given Average Recommendation of "Hold" by AnalystsMEDNAX Inc (MD) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - January 8 at 12:04 PM
$886.36 Million in Sales Expected for MEDNAX Inc (MD) This Quarter$886.36 Million in Sales Expected for MEDNAX Inc (MD) This Quarter
www.americanbankingnews.com - January 5 at 4:30 PM
[$$] The Next Deal Target in Health Care[$$] The Next Deal Target in Health Care
finance.yahoo.com - December 28 at 12:44 PM
Traders Purchase Large Volume of MEDNAX Put Options (MD)Traders Purchase Large Volume of MEDNAX Put Options (MD)
www.americanbankingnews.com - December 24 at 3:10 AM
MEDNAX (MD) Given a $55.00 Price Target at SunTrust BanksMEDNAX (MD) Given a $55.00 Price Target at SunTrust Banks
www.americanbankingnews.com - December 22 at 7:16 AM
 Analysts Anticipate Mednax, Inc (MD) to Post $0.83 EPS Analysts Anticipate Mednax, Inc (MD) to Post $0.83 EPS
www.americanbankingnews.com - December 17 at 8:38 AM
Key Risks Facing Mednax in 2017Key Risks Facing Mednax in 2017
finance.yahoo.com - December 14 at 5:48 PM
Understanding Mednax’s Financial PositionUnderstanding Mednax’s Financial Position
finance.yahoo.com - December 14 at 5:48 PM
ETFs with exposure to MEDNAX, Inc. : December 14, 2017ETFs with exposure to MEDNAX, Inc. : December 14, 2017
finance.yahoo.com - December 14 at 5:48 PM
Mednax, Inc (MD) Given Average Rating of "Hold" by AnalystsMednax, Inc (MD) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - December 14 at 2:34 PM
Mednax (MD) Coverage Initiated by Analysts at Piper Jaffray CompaniesMednax (MD) Coverage Initiated by Analysts at Piper Jaffray Companies
www.americanbankingnews.com - December 13 at 11:10 PM
The Latest Wall Street Recommendations for MednaxThe Latest Wall Street Recommendations for Mednax
finance.yahoo.com - December 13 at 5:26 PM
Mednax, Inc (MD) Insider John C. Pepia Sells 3,000 SharesMednax, Inc (MD) Insider John C. Pepia Sells 3,000 Shares
www.americanbankingnews.com - December 12 at 6:06 PM
Traders Buy Large Volume of Mednax Put Options (MD)Traders Buy Large Volume of Mednax Put Options (MD)
www.americanbankingnews.com - December 4 at 2:26 AM
Mednax volatile amidst rumored takeover interestMednax volatile amidst rumored takeover interest
seekingalpha.com - December 1 at 7:21 PM
Mednax, Inc (MD) Expected to Post Quarterly Sales of $886.36 MillionMednax, Inc (MD) Expected to Post Quarterly Sales of $886.36 Million
www.americanbankingnews.com - December 1 at 6:04 PM
Mednax fielding takeover interest from buyout firms -sourcesMednax fielding takeover interest from buyout firms -sources
finance.yahoo.com - December 1 at 4:54 PM
 Brokerages Anticipate Mednax, Inc (MD) Will Post Earnings of $0.83 Per Share Brokerages Anticipate Mednax, Inc (MD) Will Post Earnings of $0.83 Per Share
www.americanbankingnews.com - November 29 at 3:26 AM

SEC Filings

MEDNAX (NYSE:MD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

MEDNAX (NYSE:MD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

MEDNAX (NYSE MD) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.